Atlantanews Online

Excessive Daytime Sleepiness Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences

 Breaking News
  • No posts were found

Excessive Daytime Sleepiness Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences

January 17
17:50 2023
Excessive Daytime Sleepiness Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies - Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences
The Excessive Daytime Sleepiness market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Excessive Daytime Sleepiness pipeline products will significantly revolutionize the Excessive Daytime Sleepiness market dynamics.

DelveInsight’s “Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Excessive Daytime Sleepiness, historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Excessive Daytime Sleepiness market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Excessive Daytime Sleepiness market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Excessive Daytime Sleepiness Market Insights

 

Excessive Daytime Sleepiness Overview

Excessive Daytime Sleepiness (EDS) is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period. Excessive Daytime Sleepiness is often associated with a wide range of illnesses including metabolic, cardiovascular, neurological, psychiatric diseases but also with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. EDS is also commonly associated with social and economic consequences thus constituting a significant public health problem.

 

Some of the key facts of the Excessive Daytime Sleepiness Market Report: 

  • The Excessive Daytime Sleepiness market size was valued at USD 4,946 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As Excessive Daytime Sleepiness is usually considered as a symptom of other medical conditions, the diagnosis is often delayed. The patient pool suffering from EDS is mostly misdiagnosed of their condition; when the symptoms are highlighted further, they are often non-specific
  • In the epidemiology report, we have considered major indications in which Excessive Daytime Sleepiness occurs, such as Parkinson’s disease (PD), Narcolepsy, Idiopathic Hypersomnia (IH), Obstructive Sleep Apnea (OSA), and Bipolar Disorder (BD)
  • The total diagnosed prevalent population of Excessive Daytime Sleepiness in the 7MM was estimated to be 6,857,997 in 2021
  • In 2021, the diagnosed prevalent population of Excessive Daytime Sleepiness in the United States was estimated to be 3,736,749
  • Key Excessive Daytime Sleepiness Companies: Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Takeda, and others
  • Key Excessive Daytime Sleepiness Therapies: FT218, AXS-12, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, and others
  • The Excessive Daytime Sleepiness epidemiology based on gender analyzed that Excessive Daytime Sleepiness are found in OSA and Bipolar disorder, followed by Parkinson’s Disease, Narcolepsy, and Idiopathic Hypersomnia

 

Get a Free sample for the Excessive Daytime Sleepiness Market Report – 

https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

 

Key benefits of the Excessive Daytime Sleepiness Market report:

  1. Excessive Daytime Sleepiness market report covers a descriptive overview and comprehensive insight of the Excessive Daytime Sleepiness Epidemiology and Excessive Daytime Sleepiness market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Excessive Daytime Sleepiness market report provides insights on the current and emerging therapies.
  3. Excessive Daytime Sleepiness market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Excessive Daytime Sleepiness market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Excessive Daytime Sleepiness market.

 

Download the report to understand which factors are driving Excessive Daytime Sleepiness epidemiology trends @ Excessive Daytime Sleepiness Epidemiological Insights 

 

Excessive Daytime Sleepiness Market  

The dynamics of the Excessive Daytime Sleepiness market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The emerging pipeline for EDS have Avadel Pharmaceutical’s FT218, a once nightly formulation version of sodium oxybate, Axsome Therapeutics’s AXS12 (reboxetine), Theranexus’s THN102,and few other potential products in development. The emerging drugs are in late, middle and in early stage of development. Probably in coming couple of years, some of these emerging products will be in market”

 

Excessive Daytime Sleepiness Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Excessive Daytime Sleepiness Epidemiology Segmentation:

The Excessive Daytime Sleepiness market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Excessive Daytime Sleepiness
  • Prevalent Cases of Excessive Daytime Sleepiness by severity
  • Gender-specific Prevalence of Excessive Daytime Sleepiness
  • Diagnosed Cases of Episodic and Chronic Excessive Daytime Sleepiness

 

Excessive Daytime Sleepiness Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to get launched during the study period. The analysis covers Excessive Daytime Sleepiness market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Excessive Daytime Sleepiness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Excessive Daytime Sleepiness market share @ Excessive Daytime Sleepiness market forecast 

 

Excessive Daytime Sleepiness Therapies and Key Companies

  • FT218: Avadel Pharmaceuticals
  • AXS-12: Axsome Therapeutics
  • THN102: Theranexus
  • SUVN-G3031: Suven LifeSciences
  • Quilience: NLS Pharma
  • XW10172: XWPharma
  • TAK-994: Takeda

 

Excessive Daytime Sleepiness Market Drivers

  • Robust clinical pipeline
  • Support of the US FDA by granting designations
  • Recent launch of Xywav and Ozawade
  • Increasing prevalence due to appearance of Excessive Daytime Sleepiness as a symptom in various disorders

 

Scope of the Excessive Daytime Sleepiness Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Excessive Daytime Sleepiness Companies: Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Takeda, and others
  • Key Excessive Daytime Sleepiness Therapies: FT218, AXS-12, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, and others
  • Excessive Daytime Sleepiness Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and Excessive Daytime Sleepiness emerging therapies
  • Excessive Daytime Sleepiness Market Dynamics: Excessive Daytime Sleepiness market drivers and Excessive Daytime Sleepiness market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Excessive Daytime Sleepiness Unmet Needs, KOL’s views, Analyst’s views, Excessive Daytime Sleepiness Market Access and Reimbursement 

 

Excessive Daytime Sleepiness Market Barriers

  • High cost of therapies
  • Delay in diagnosis
  • A limited number of participants
  • Lack of practical measurement tools in diagnosis

 

Table of Contents 

1. Excessive Daytime Sleepiness Market Report Introduction

2. Executive Summary for Excessive Daytime Sleepiness

3. SWOT analysis of Excessive Daytime Sleepiness

4. Excessive Daytime Sleepiness Patient Share (%) Overview at a Glance

5. Excessive Daytime Sleepiness Market Overview at a Glance

6. Excessive Daytime Sleepiness Disease Background and Overview

7. Excessive Daytime Sleepiness Epidemiology and Patient Population

8. Country-Specific Patient Population of Excessive Daytime Sleepiness 

9. Excessive Daytime Sleepiness Current Treatment and Medical Practices

10. Excessive Daytime Sleepiness Unmet Needs

11. Excessive Daytime Sleepiness Emerging Therapies

12. Excessive Daytime Sleepiness Market Outlook

13. Country-Wise Excessive Daytime Sleepiness Market Analysis (2019–2032)

14. Excessive Daytime Sleepiness Market Access and Reimbursement of Therapies

15. Excessive Daytime Sleepiness Market Drivers

16. Excessive Daytime Sleepiness Market Barriers

17.  Excessive Daytime Sleepiness Appendix

18. Excessive Daytime Sleepiness Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Excessive Daytime Sleepiness treatment, visit @ Excessive Daytime Sleepiness Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Related Articles

Categories